Last updated: August 10, 2026
EPANED is a 1 mg/mL oral solution of enalapril maleate designed for patients who cannot reliably swallow tablets, including pediatric and geriatric patients. Its commercial value is tied less to the active ingredient, which is generic, than to liquid-dose convenience, palatability, dose accuracy, stability, and access to underserved formulation segments. The strongest opportunities are pediatric hypertension, heart failure, dysphagia, enteral-tube administration, hospital discharge, and line extensions with differentiated packaging or concentration.
What is EPANED and who manufactures it?
EPANED contains enalapril maleate, an angiotensin-converting enzyme inhibitor used for hypertension and heart failure-related indications. The product is supplied as a 1 mg/mL oral solution under FDA NDA 207635. Public FDA labeling identifies Azurity Pharmaceuticals as the sponsor and manufacturer of record for the marketed product.[1]
| Product attribute |
EPANED information |
| Active ingredient |
Enalapril maleate |
| Dosage form |
Oral solution |
| Strength |
1 mg/mL |
| FDA application |
NDA 207635 |
| Primary patient need |
Patients unable to use solid oral dosage forms |
| Key markets |
Pediatric, geriatric, dysphagia, home care, hospital discharge |
| Regulatory pathway |
505(b)(2) or abbreviated pathway may be relevant for follow-on liquid products, depending on formulation and reference product strategy |
| Competitive issue |
Enalapril tablets and compounded oral liquids are lower-cost alternatives |
The product's commercial differentiation comes from a ready-to-use liquid formulation. Enalapril tablets are widely available, but tablet manipulation can create dose-uniformity, stability, caregiver, and administration problems.
What excipients are used in EPANED?
The FDA-approved EPANED formulation uses excipients selected for pH control, viscosity, sweetness, and palatability. Public labeling identifies citric acid, sodium citrate, hydroxyethyl cellulose, sucralose, and flavoring components among the inactive ingredients.[1,2]
| Excipient function |
EPANED formulation role |
Commercial relevance |
| Citric acid |
Acidification and pH adjustment |
Supports chemical stability and taste control |
| Sodium citrate |
Buffering |
Helps maintain formulation pH during storage |
| Hydroxyethyl cellulose |
Viscosity modification |
Supports dose uniformity and mouthfeel |
| Sucralose |
High-intensity sweetener |
Improves palatability without conventional sugar loading |
| Flavor system |
Taste masking |
Reduces bitterness associated with enalapril and formulation acidity |
| Purified water |
Vehicle |
Standard aqueous medium for oral administration |
The precise concentration of each inactive ingredient is generally not disclosed in the prescribing information. That information may be available through regulatory submissions, supplier documentation, development reports, or product-specific analytical work.
How should an excipient strategy for EPANED be designed?
A follow-on formulation should prioritize five technical objectives: chemical stability, microbial control, palatability, dosing accuracy, and compatibility with administration devices.
1. Control pH without excessive acidity
Enalapril maleate is susceptible to degradation in aqueous environments. A citrate buffer can provide pH control, but excessive acidity may reduce acceptability, particularly in children. Development should evaluate a narrow pH range that balances:
- Enalapril maleate assay and degradation products
- Taste and oral irritation
- Preservative performance
- Container compatibility
- Long-term and in-use stability
Alternative buffers, including phosphate or acetate systems, may create different stability and taste profiles. A non-citrate formulation could provide a meaningful formulation distinction if it improves stability or reduces acid taste, but the regulatory burden would increase if the change affects bioavailability or impurity formation.
2. Optimize viscosity for dose accuracy
Hydroxyethyl cellulose can improve suspension uniformity and mouthfeel, but excessive viscosity creates practical problems:
- Inaccurate withdrawal from oral syringes
- Slow bottle drainage
- Residual product in the container
- Difficult administration through feeding tubes
- Increased risk of air bubbles in dosing devices
The preferred viscosity target should be established using the intended oral syringe, bottle adapter, and enteral-tube sizes. A lower-viscosity formulation could be commercially attractive if it preserves dose accuracy while improving tube administration.
3. Use taste masking that does not impair stability
Enalapril formulations may present bitterness, acidity, or aftertaste. Sucralose and flavoring are established approaches, but pediatric preferences vary by age and geography. Commercial development should test:
- Fruit flavors for younger children
- Neutral or unflavored variants for tube-fed patients
- Reduced-sweetener options for chronic use
- Flavor persistence after dilution
- Compatibility with milk, water, and common administration vehicles
A formulation with improved palatability could support adherence, but taste claims require controlled sensory evidence and must not imply clinical superiority without supporting data.
4. Select the preservative strategy carefully
A preservative-free product can reduce concerns about chronic exposure and excipient sensitivity, but it raises manufacturing, packaging, and in-use stability requirements. A preserved product may provide longer in-use dating and greater distribution flexibility.
Possible strategies include:
- Preservative-free unit-dose packaging
- Multidose packaging with validated microbial protection
- Alternative preservative systems
- Advanced bottle-closure systems that reduce contamination
- Ready-to-administer prefilled oral syringes
Any preservative change requires antimicrobial effectiveness testing, extractables and leachables assessment, and stability testing under opened-bottle conditions.[3]
What formulation patents could protect an EPANED follow-on product?
The strongest patent opportunities would likely involve the formulation architecture rather than enalapril itself. Enalapril and enalapril maleate are established active pharmaceutical ingredients, making broad composition claims difficult to obtain.
Potential claim categories include:
-
Specific pH and buffer ranges
Claims could cover a defined enalapril concentration, citrate level, and pH range if the combination produces unexpected stability or palatability.
-
Preservative-free aqueous formulations
Patent protection may focus on a multidose formulation that remains microbiologically acceptable without conventional preservatives.
-
Low-viscosity, dose-accurate liquids
Claims could combine viscosity, syringe withdrawal force, dose uniformity, and container geometry.
-
Enteral-tube-compatible formulations
A formulation that limits adsorption, clogging, foaming, or dose loss in feeding tubes could support hospital and home-care applications.
-
Taste-masking systems
A defined flavor, sweetener, buffer, and active-ingredient combination may be patentable if supported by comparative sensory and stability data.
-
Unit-dose or prefilled delivery systems
Packaging claims may cover dose-specific syringes, tamper-evident systems, or pediatric dosing kits.
-
Stability-enhancing manufacturing processes
Claims could target order of addition, deaeration, mixing temperature, filling conditions, or packaging materials that reduce degradation.
A credible patent program should generate comparative data against EPANED, compounded enalapril solutions, and commercially available enalapril tablets dispersed before administration. Patentability depends on unexpected results, claim scope, enablement, and prior art.
What is the Orange Book status of EPANED?
EPANED is approved under NDA 207635. The Orange Book should be reviewed for current patent and exclusivity listings before a paragraph IV strategy, licensing transaction, or launch decision. The principal commercial barrier is likely to be formulation and regulatory execution rather than the active ingredient.
For a competing product, the key Orange Book questions are:
- Whether any EPANED patents are listed for the NDA
- Whether listed patents cover the formulation, method of use, or delivery system
- Whether pediatric exclusivity or other regulatory exclusivity remains active
- Whether the proposed product can rely on an ANDA or requires a 505(b)(2) application
- Whether the applicant must certify to listed patents under Paragraph IV
A 505(b)(2) applicant may have greater flexibility where the proposed product differs from tablet products in dosage form, concentration, excipients, labeling, or delivery device. The pathway does not eliminate patent risk. It shifts the analysis toward listed patents, nonlisted formulation patents, data requirements, and the scope of the proposed labeling.
When does EPANED lose exclusivity?
The active ingredient has long been generic, so product-level exclusivity depends on FDA regulatory exclusivity and patent status associated with the NDA. No reliable commercial conclusion should be based solely on the age of enalapril or the existence of generic tablets.
The relevant timeline is:
| Event |
Commercial significance |
| Enalapril tablet approval |
Active-ingredient competition established |
| EPANED NDA approval |
Liquid formulation entered the branded market |
| Patent listing review |
Determines whether an ANDA applicant faces Orange Book certifications |
| Regulatory exclusivity review |
Determines whether FDA can approve a competing application |
| Paragraph IV filing |
May trigger patent litigation and a 30-month stay |
| First generic or 505(b)(2) approval |
Establishes regulatory competition |
| Commercial launch |
Depends on litigation, settlement, manufacturing readiness, and reimbursement |
A separate liquid formulation may remain commercially defensible after patent expiry if it has strong pharmacy distribution, pediatric adoption, hospital protocols, and favorable reimbursement.
Which companies could challenge or compete with EPANED?
Competition falls into four groups:
Generic manufacturers
Large generic companies can develop an enalapril oral solution through an ANDA if the reference-product requirements and product-specific regulatory pathway permit it. Their advantages are manufacturing scale, payer access, and low-cost distribution.
Specialty pharmaceutical companies
Specialty companies focused on pediatric, rare disease, or hospital products may pursue a 505(b)(2) product with differentiated concentration, taste, packaging, or administration technology.
Compounding pharmacies
Compounded enalapril liquids compete on price and local availability. Their disadvantages include variable availability, shorter beyond-use dating, pharmacy-level preparation, and less standardized packaging.
Hospital and health-system pharmacies
Institutional pharmacies may prepare extemporaneous liquid formulations for inpatient use. This is a larger threat to hospital demand than to retail prescriptions.
What commercial opportunities exist for EPANED excipients?
The highest-value opportunities are product extensions that solve administration problems rather than merely substitute one sweetener or buffer for another.
Pediatric line extensions
A 0.5 mg/mL presentation could improve dose measurement for infants and small children. A 2 mg/mL concentration could reduce volume for older children and adults, but it would increase the risk of tenfold dosing errors. Any concentration change would require strong labeling, device controls, and human-factors testing.
Prefilled oral syringes
Prefilled syringes could reduce caregiver measurement errors and improve hospital discharge adherence. They also provide a packaging-based differentiation strategy that may be harder for low-cost generic competitors to reproduce immediately.
Enteral feeding-tube products
A tube-compatible formulation with validated administration instructions could address a defined hospital and home-care segment. Data should cover tube retention, adsorption, flushing volume, dose recovery, and compatibility with commonly used tube materials.
Preservative-free unit doses
Unit-dose packaging could target neonatal, pediatric, and chronic-care settings where preservative exposure is a concern. The tradeoff is higher packaging cost and more complex supply-chain requirements.
Global-market formulation
A formulation using widely accepted excipients and avoiding regionally restricted flavoring or preservative systems could support international registration. Geographic expansion would require country-specific excipient, labeling, stability, and device reviews.
How strong is the EPANED patent and formulation estate?
The estate is likely strongest when it protects a tested combination of formulation, packaging, and administration performance. Broad enalapril composition claims are less likely to provide durable exclusion because the active ingredient is established and multiple oral-liquid approaches are known.
Commercial strength should be assessed across four dimensions:
| Dimension |
Strong position |
Weak position |
| Formulation |
Narrow, reproducible stability and taste advantage |
Routine buffer and sweetener substitution |
| Delivery |
Validated device or tube-administration advantage |
Standard bottle and syringe |
| Regulatory |
Clear pathway with limited clinical-data burden |
Bioavailability or bridging uncertainty |
| Market access |
Pediatric and hospital protocol adoption |
Reliance on premium pricing alone |
Key Takeaways
- EPANED is a 1 mg/mL enalapril maleate oral solution approved under NDA 207635.
- Its commercial differentiation is liquid administration, not active-ingredient novelty.
- Core excipient functions are buffering, viscosity control, sweetening, flavor masking, and aqueous vehicle selection.
- The most promising product extensions are pediatric concentrations, prefilled syringes, preservative-free unit doses, and enteral-tube-compatible packaging.
- Patent value is likely to come from formulation-performance combinations, delivery systems, and manufacturing controls.
- Generic tablets and compounded liquids remain the primary competitive threats.
- A competing product must resolve the Orange Book, regulatory exclusivity, ANDA or 505(b)(2), Paragraph IV, and formulation-patent issues before launch planning.
FAQs
Can EPANED be reformulated with a different sweetener?
Yes, but the substitute must be evaluated for taste, chemical compatibility, preservative performance, stability, and pediatric acceptability. A sweetener change alone may provide limited patent differentiation unless it produces an unexpected technical result.
Is a higher-strength EPANED formulation commercially attractive?
Potentially. A higher concentration could reduce administration volume, but it would increase dosing-error risk. The opportunity is strongest in older children, adults with dysphagia, and enteral-tube users, subject to device and human-factors validation.
Could a preservative-free enalapril solution compete with EPANED?
Yes. A preservative-free product could target pediatric and chronic-use segments, particularly if packaged in unit doses. The key technical barriers are microbial control, in-use dating, container integrity, and manufacturing cost.
Does a compounded enalapril solution have the same commercial profile as EPANED?
No. Compounding may offer lower cost or local access, but it generally has different quality controls, packaging, stability dating, and distribution characteristics. Those differences can support a branded ready-to-use product.
What is the most defensible patent strategy for an EPANED competitor?
The strongest strategy would combine a defined liquid formulation with validated stability, taste masking, dosing-device performance, enteral-tube compatibility, or preservative-free multidose protection. Broad claims covering enalapril in water are unlikely to provide equivalent strength.
References
- U.S. Food and Drug Administration. (2024). EPANED (enalapril maleate) oral solution prescribing information.
- National Library of Medicine. (2024). DailyMed: EPANED enalapril maleate solution.
- U.S. Food and Drug Administration. (2016). Q1A(R2) stability testing of new drug substances and products.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
